Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | PPIA | P62937 | 3/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1451862 | 1.00 | MEN1 (0.56) | MEN1KMT2ARXFP1PPIATRPV1 | |
| SCHEMBL1450392 | 0.89 | TRPV1 (0.42) | MEN1KMT2ARXFP1TRPV1ROCK2 | |
| SCHEMBL1450913 | 0.87 | TRPV1 (0.41) | MEN1KMT2ARXFP1TRPV1ALDH1A1 | |
| SCHEMBL1450919 | 0.87 | TRPV1 (0.41) | MEN1KMT2ARXFP1TRPV1ALDH1A1 | |
| SCHEMBL1450631 | 0.86 | TRPV1 (0.47) | MEN1KMT2ARXFP1TRPV1ROCK2 | |
| SCHEMBL1450627 | 0.86 | TRPV1 (0.47) | MEN1KMT2ARXFP1TRPV1ROCK2 | |
| SCHEMBL3591854 | 0.86 | TRPV1 (0.47) | MEN1KMT2ARXFP1TRPV1 | |
| SCHEMBL1451013 | 0.86 | TRPV1 (0.41) | MEN1KMT2ARXFP1TRPV1ROCK2 | |
| SCHEMBL1451423 | 0.85 | PARP10 (0.49) | MEN1KMT2ARXFP1TRPV1ROCK2 | |
| SCHEMBL12629773 | 0.85 | TRPV1 (0.54) | MEN1KMT2ATRPV1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383839-B2 | Heterocyclidene acetamide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-26 | — | — | US | claimed |
| US-20110112071-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-05-12 | — | — | US | claimed |
| US-8383839-B2 | Heterocyclidene acetamide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-26 | — | — | US | disclosed |
| US-20110112071-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20080287428-A1 | Novel Heterocyclidene Acetamide Derivative | MOCHIDA PHARMACEUTICAL CO.,LTD (JP) | 2008-11-20 | — | — | US | disclosed |
| EP-1908753-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287428-A1 | Novel Heterocyclidene Acetamide Derivative | TRPV1, TRPV3, TRPA1 | MEN1 4073/4885KMT2A 3094/4885RXFP1 336/4885 |
| US-20110112071-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | TRPV1, TRPV3, TRPA1 | MEN1 4073/4885KMT2A 3094/4885RXFP1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.